| Name | Title | Contact Details |
|---|
OurCrowd is a global venture investing platform that empowers institutions and individuals to invest and engage in emerging companies. The most active venture investor in Israel, OurCrowd vets and selects companies, invests its capital, and provides its global network with unparalleled access to co-invest and contribute connections, talent and deal flow. OurCrowd builds value for its portfolio companies throughout their lifecycles, providing mentorship, recruiting industry advisors, navigating follow-on rounds and creating growth opportunities through its network of multinational partnerships. OurCrowd has more than $1B in committed funds for its 200+ portfolio companies and venture funds.
Third Kind Venture Capital is a New York-based venture capital fund focused on early-stage investments.
TriLinc Global, LLC is the world's first impact investment firm dedicated to harnessing the collective power of main street investors in the United States to help businesses in developing countries create jobs, grow the middle class and generate measurable positive impact. Founded by a team of proven investors and entrepreneurs, TriLinc Global is dedicated to the idea that positive economic growth, social progress and environmental sustainability can and must go hand and hand. The Company currently operates in the U.S., Latin America and South Asia and invests capital through a series of proprietary funds, with a new focus on non-traded SEC registered retail fund vehicles, which pay a fixed current dividend, offer long-term capital appreciation potential and produce measurable social and/or environmental impact results. TriLinc currently oversees four U.S.-focused private equity funds and has $85 million in total assets under management/advisement.
Exceptional leaders come here to study general management, product development, marketing, finance, and business analytics. Our goal is to help them succeed in their life`s work -- managing creative destruction.
Our team has a proven record of translating disruptive technologies into valuable business enterprises. Working closely with leading scientific and business visionaries as well as industry partners, we identify opportunities to change the future of medicine and rigorously vet those ideas through our discovery process to develop the vision, strategy and plan needed to succeed.